Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

8.10
+0.64008.58%
Pre-market: 8.100.0029+0.04%08:47 EDT
Volume:908.33K
Turnover:7.16M
Market Cap:409.17M
PE:-2.36
High:8.13
Open:7.56
Low:7.53
Close:7.46
52wk High:13.48
52wk Low:5.04
Shares:50.51M
Float Shares:41.40M
Volume Ratio:1.30
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4333
EPS(LYR):-4.5871
ROE:-62.49%
ROA:-17.88%
PB:1.91
PE(LYR):-1.77

Loading ...

Regenxbio Inc. Announces FDA Acceptance and Priority Review of RGX-121 for MPS II; PDUFA Target Action Date Set for November 9, 2025

Reuters
·
May 13

Bank of America Securities Sticks to Its Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
May 13

Regenxbio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

BRIEF-Regenxbio Q1 Net Income USD 6.083 Million

Reuters
·
May 13

Regenxbio Q1 EPS $0.12 Misses $0.22 Estimate, Sales $89.01M Miss $101.97M Estimate

Benzinga
·
May 13

Regenxbio Inc expected to post earnings of 48 cents a share - Earnings Preview

Reuters
·
May 10

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks
·
May 05

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

PR Newswire
·
May 01

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)

TIPRANKS
·
Apr 30

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Dow Jones
·
Apr 22

REGENXBIO Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Apr 18

RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 03

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
Apr 01

REGENXBIO Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 20

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 20

BUZZ-Regenxbio rises on early data from gene therapy for muscle disorder

Reuters
·
Mar 19

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy

MT Newswires Live
·
Mar 19

Regenxbio Shares Rise After Positive Trial Data for RGX-202

Dow Jones
·
Mar 19

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

PR Newswire
·
Mar 19

Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley

TIPRANKS
·
Mar 18